<DOC>
	<DOC>NCT02987777</DOC>
	<brief_summary>The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)</brief_summary>
	<brief_title>Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer Stage IIIIV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci A patient record captured outside the time frame from January 2004 to December 2014</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>